CannaRoyalty announced its investee Resolve Digital Health signed an exclusive agreement with Aphria.
The agreement will provide Resolve with a Canadian source of high quality cannabis products, which will be packaged and sold in its proprietary Breeze Smart Inhaler™ metered dosing system pods and cartridges.
Resolve’s Breeze Smart Inhalers provide accurate, metered, treatment solutions with pre-packaged, single use Smartpods™ that will now be filled with Aphria’s high quality dried herb or extract once the products launch in Canada. The inhalers use machine-learning algorithms to provide patients with learned dosing and strain selection appropriate to their medical condition, continuously improving the patient’s experience and the efficacy of the product.
“This agreement marks a significant milestone for Resolve as it prepares for commercial launch in the Canadian marketplace, following its successful financing earlier this year,” said Marc Lustig, CEO of CannaRoyalty. “We look forward to our continued partnership and to supporting Resolve in their brand development and distribution goals across North America.”